1. bookVolume 29 (2021): Edizione 4 (October 2021)
Dettagli della rivista
License
Formato
Rivista
eISSN
2284-5623
Prima pubblicazione
08 Aug 2013
Frequenza di pubblicazione
4 volte all'anno
Lingue
Inglese
access type Accesso libero

Mutations in the KRAS gene as a predictive biomarker of therapeutic response in patients with colorectal cancer

Pubblicato online: 22 Oct 2021
Volume & Edizione: Volume 29 (2021) - Edizione 4 (October 2021)
Pagine: 365 - 375
Ricevuto: 06 Oct 2021
Accettato: 11 Oct 2021
Dettagli della rivista
License
Formato
Rivista
eISSN
2284-5623
Prima pubblicazione
08 Aug 2013
Frequenza di pubblicazione
4 volte all'anno
Lingue
Inglese
Abstract

Introduction: Despite the important role of general KRAS mutational status in the selection of an adequate therapeutic protocol in patients with colorectal cancer (CRC), studies that focus on its specific mutations and their significance on progression of disease are scarce. This study aimed to determine the significance of specific KRAS mutations in response to standard chemotherapy protocols with oxaliplatin-based (FOLFOX 4, OXFL) in the first-line and irinotecan-based chemotherapy (FOLFIRI, IFL) in the second-line therapy, and to evaluate the correlation between these mutations and clinicopathological characteristics of CRC patients.

Methods: Genomic DNA was extracted from the FFPE tumour tissue sections while the KRAS mutation test was performed by using PCR methods.

Results: Prevalence of KRAS gene mutations in CRC patients was 45%. Mutated KRAS was more frequent in later stages of tumor infiltrations (P =0.0017), on the right side of the colon (P= 0.0044), and in patients who developed metastases in the first 6 months after CRC diagnosis than in patients who developed metastases after 24 months (P=0.0083). In a group of patients with a poor therapeutic response to standard chemotherapy the most frequent mutations in KRAS gene were G12D and G12V (63.88%), while in a group of patients with a good response to therapeutic protocols the most prevalent mutation was G12A (66.66%).

Conclusion: Our results indicate that there was a significant difference in biological behaviour between tumours harboring different mutations in KRAS gene. Overall, mutation G12A could be a novel prognostic biomarker for CRC patients treated with standard chemotherapy.

Keywords

1. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89-103. DOI: 10.5114/pg.2018.8107210.5114/pg.2018.81072679113431616522 Search in Google Scholar

2. Campos FG. Colorectal cancer in young adults: A difficult challenge. World J Gastroenterol. 2017;23(28):5041-5044. DOI: 10.3748/wjg.v23. i28.5041 Search in Google Scholar

3. Connell LC, Mota JM, Braghiroli MI, Hoff PM. The Rising Incidence of Younger Patients With Colorectal Cancer: Questions About Screening, Biology, and Treatment. Curr Treat Options Oncol. 2017;18(4):23. DOI: 10.1007/s11864-017-0463-310.1007/s11864-017-0463-328391421 Search in Google Scholar

4. Mármol I, Sánchez-de-Diego C, Pradilla DA, Cerrada E, Rodriguez Yoldi MJ. Colorectal carcinoma: A general overview and future perspectives in colorectal cancer. Int J Mol Sci. 2017;18(1):197. DOI: 10.3390/ ijms1801019710.3390/ijms18010197529782828106826 Search in Google Scholar

5. Recio-Boiles A, Cagir B. Colon Cancer. [Updated 2021 Jan 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470380/ Search in Google Scholar

6. Maffeis V, NicolèL, Cappellesso R. RAS, cellular plasticity, and tumor budding in colorectal cancer. FronOncol. 2019;9;1255. DOI: 10.3389/fonc.2019.0125510.3389/fonc.2019.01255687775331803624 Search in Google Scholar

7. Buday L, Downward J. Many faces of Ras activation. Biochimica et Biophysica Acta. 2008;1786(2):178-87. DOI: 10.1016/j.bbcan.2008.05.00110.1016/j.bbcan.2008.05.00118541156 Search in Google Scholar

8. Takács T, Kudlik G, Kurilla A, Szeder B, Buday L, Vas V. The effects of mutant Ras proteins on the cell signalome. Cancer Metastasis Rev. 2020;39:1051-65. DOI: 10.1007/s10555-020-09912-810.1007/s10555-020-09912-8768033732648136 Search in Google Scholar

9. Hwang K, Yoon JH, Lee JH, Lee S. Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers Biomedicines. 2021; 9(1):39. DOI: 10.3390/biomedicines901003910.3390/biomedicines9010039782481633466394 Search in Google Scholar

10. Porebska I, Harlozińska A, Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol. 2000;21(2):105-15. DOI: 10.1159/00003011610.1159/00003011610686540 Search in Google Scholar

11. Dassonville O, Bozec A, Fischel JL, Milano G. EGFR targeting therapies: Monoclonal antibodies versus tyro-sine kinase inhibitors. Similarities and differences. Crit Rev Oncol Hematol. 2007;62:53-61. DOI: 10.1016/j. critrevonc.2006.12.008 Search in Google Scholar

12. Porru M, Pompili L, Caruso C, Biroccio A, Leonetti C. Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities. J Exp Clin Cancer Res. 2018;37(1):57. DOI: 10.1186/s13046-018-0719-110.1186/s13046-018-0719-1585091329534749 Search in Google Scholar

13. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, et al. Association of KRAS p.G13D mutation with outcome in patients with chemo-therapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010;304(16):1812-20. DOI: 10.1001/jama.2010.153510.1001/jama.2010.153520978259 Search in Google Scholar

14. BankovicLazarević D, Krivokapić Z, Barišić G, Jovanović V, Ilić D, Veljković M. Organized colorectal cancer screening in Serbia - the first round within 2013-2014. Vojnosanit Pregl. 2016;73:360-7. DOI: 10.2298/ VSP150421113B10.2298/VSP150421113B29309104 Search in Google Scholar

15. Vekic B, Dragojevic-Simic V, Jakovljevic M, Pilipovic F, Simic R, Zivic R, et al. Medical cost of colorectal cancer services in Serbia between 2014 and 2017: National data report. Front Pharmacol. 2019;10:526. DOI: 10.3389/fphar.2019.0052610.3389/fphar.2019.00526653040531156439 Search in Google Scholar

16. Patel A, Tripathi G, Gopalakrishnan K, Williams N, Arasaradnam RP. Field cancerisation in colorectal cancer: a new frontier or pastures past? World J Gastroenterol. 2015;21(13):3763-72. DOI: 10.3748/wjg.v21. i13.3763 Search in Google Scholar

17. Lea IA, Jackson MA, Li X, Bailey S, Peddada SD and Dunnick JK. Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns. Carcinogenesis. 2007;28:1851-8. DOI: 10.1093/carcin/ bgm176 Search in Google Scholar

18. Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: A meta-analysis of randomized, controlled trials. Ann Oncol. 2015;26:13-21. DOI: 10.1093/annonc/mdu37810.1093/annonc/mdu37825115304 Search in Google Scholar

19. Garcia-Carbonero N, Martinez-Useros J, Li W, Orta A, Perez N, Carames C, et al. KRAS and BRAF mutations as prognostic and predictive biomarkers for standard chemotherapy response in metastatic colorectal cancer: A single institutional study. Cells 2020;9(1):219. DOI: 10.3390/cells901021910.3390/cells9010219701663431952366 Search in Google Scholar

20. Bruera G, Cannita K, Di Giacomo D, Lamy A, FrébourgT, Sabourin JS, et al. Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemo-therapy plus bevacizumab (FIr-B/FOx). BMC Med. 2013;11:59. DOI: 10.1186/1741-7015-11-5910.1186/1741-7015-11-59363586923497191 Search in Google Scholar

21. Jones RP, Sutton PA, Evans JP, Clifford R, McAvoy A, Lewis J, et al. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. Br J Cancer. 2017;116(7):923-9. DOI: 10.1038/bjc.2017.3710.1038/bjc.2017.37537914928208157 Search in Google Scholar

22. Sirisena ND, Deen K, Mandawala DEN, Herath P, Dissanayake VHW. The pattern of KRAS mutations in metastatic colorectal cancer: a retrospective audit from Sri Lanka. BMC Research Notes. 2017;10(1):392. DOI: 10.1186/s13104-017-2731-510.1186/s13104-017-2731-5555360628797274 Search in Google Scholar

23. SadoughA, Afshari M, Rostami F, Berzegari S, Janbabaee G, Tabrizi R, et al. A systematic review and meta-analysis on the prevalence of KRAS gene mutation in samples of colorectal cancer. WCRJ. 2020;7:e1522. Search in Google Scholar

24. Jakovljevic K, Malisic E, Cavic M, Krivokuca A, Dobricic J, Jankovic R. KRAS and BRAF mutations in Serbian patients with colorectal cancer. J BUON. 2012;17(3):575-80. Search in Google Scholar

25. Jankovic R, Brotto K, MalisicE,Krivokuca A, Cavic M, Jovanovic K, Boljevic I, Tanic M, Radulovic S. KRAS mutations in colorectal cancer patients in Serbia: 5 years experience of central testing. Ann Oncol. 2014;25 (Supplement 2): ii14-ii104. Search in Google Scholar

26. Awidi M, Ababneh N, Shomaf M, AlFararjeh F, Owaidi L, Al Khatib M, et al. KRAS and NRAS mutational gene profile of metastatic colorectal cancer patients in Jordan. PloS One. 2019;14(12):e0226473. DOI: 10.1371/journal.pone.022647310.1371/journal.pone.0226473693428831881025 Search in Google Scholar

27. Korphaisarn K, Pongpaibul A, Roothumnong E,Pong-suktavorn K, Thamlikitkul L, Anekpuritanang T, et al. High frequency of KRAS codon 146 and FBXW7 mutations in Thai patients with stage II-III colon cancer. Asian Pac J CancerPrev. 2019;20(8):2319-26. DOI: 10.31557/APJCP.2019.20.8.231910.31557/APJCP.2019.20.8.2319685281931450901 Search in Google Scholar

28. Xie MZ, Li JL, Cai ZM, Li KZ, Hu BL. Impact of primary colorectal cancer location on the KRAS status and its prognostic value. BMC Gastroenterol. 2019;19(1):46. DOI: 10.1186/s12876-019-0965-510.1186/s12876-019-0965-5643798530917791 Search in Google Scholar

29. Bylsma LC, Gillezeau C, GarawinTA,Kelsh MA, Fryzek JP, Sangare L, Lowe KA.Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis. Cancer Med. 2020;9(3):1044-57. DOI: 10.1002/cam4.274710.1002/cam4.2747699709531856410 Search in Google Scholar

30. Baran B, OzupekNM, Tetik NY, Acar E, Bekcioglu O, Baskin Y. Difference between left-sided and right-sided colorectal cancer: a focused review of literature. Gastroenterology Res. 2018;11:264-73. DOI: 10.14740/ gr1062w10.14740/gr1062w608958730116425 Search in Google Scholar

31. Dai D, Wang Y, Zhu L, Jin H, Wang X. Prognostic value of KRAS mutation status in colorectal cancer patients: a population-based competing risk analysis. Peer J. 2020;8:e9149. DOI: 10.7717/peerj.914910.7717/peerj.9149727188732547859 Search in Google Scholar

32. Li W, Qiu T, Zhi W, Shi S, Zou S, Ling Y, Shan L, Ying J, Lu N. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages BMC Cancer. 2015;15:340. DOI: 10.1186/ s12885-015-1345-310.1186/s12885-015-1345-3442310725929517 Search in Google Scholar

33. Hunter JC, Manandhar A, Carrasco MA, Gurbani D, Gondi S, Westover KD. Biochemical and structural analysis of common cancer-associated KRAS mutations. MolCancer Res. 2015;13:1325-35. DOI: 10.1158/1541-7786.MCR-15-020310.1158/1541-7786.MCR-15-020326037647 Search in Google Scholar

34. Mu-oz-Maldonado C, Zimmer Y, Medová M. A Comparative Analysis of Individual RAS Mutations in Cancer Biology. Front Oncol. 2019;18;9:1088. DOI: 10.3389/fonc.2019.0108810.3389/fonc.2019.01088681320031681616 Search in Google Scholar

35. Fiala O, Buchler T, Mohelnikova-Duchonova B, Melichar B, Matejka VM, Holubec L, Kulhankova J, Bortlicek Z, Bartouskova M, Liska V, Topolcan O, Sedivcova M, Finek J. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. Tumour Biol. 2016;37(5):6823-30. DOI: 10.1007/s13277-015-4523-710.1007/s13277-015-4523-726662311 Search in Google Scholar

Articoli consigliati da Trend MD

Pianifica la tua conferenza remota con Sciendo